Melissa O’Gorman

Impact of Acid‐Reducing Agents on the Pharmacokinetics of Palbociclib, a Weak Base With pH‐Dependent Solubility, With Different Food Intake Conditions

Wan Sun, Karen J. Klamerus, Lisa M. Yuhas et al. · Clinical Pharmacology in Drug Development · 2017 · 77 citations

A Highly Selective, Non-Hydantoin, Non-Carboxylic Acid Inhibitor of Aldose Reductase with Potent Oral Activity in Diabetic Rat Models:  6-(5-Chloro-3-methylbenzofuran- 2-sulfonyl)-2-<i>H</i>-pyridazin-3-one

Banavara L. Mylari, Sandra J. Armento, David A. Beebe et al. · Journal of Medicinal Chemistry · 2003 · 68 citations · Full text

Oral Bioavailability, Aldo-keto Reductase, Glycobiology +17

A Novel Series of Non-Carboxylic Acid, Non-Hydantoin Inhibitors of Aldose Reductase with Potent Oral Activity in Diabetic Rat Models:  6-(5-Chloro-3-methylbenzofuran-2-sulfonyl)-2<i>H</i>-pyridazin-3-one and Congeners

Banavara L. Mylari, Sandra J. Armento, David A. Beebe et al. · Journal of Medicinal Chemistry · 2005 · 65 citations · Full text

Medicinal Chemistry, Aldo-keto Reductase, Biochemistry +15

Metabolism, excretion and pharmacokinetics of [¹⁴C]crizotinib following oral administration to healthy subjects

Theodore R. Johnson, Weiwei Tan, Lance Goulet et al. · Xenobiotica · 2014 · 56 citations

The Bioequivalence of Tafamidis 61‐mg Free Acid Capsules and Tafamidis Meglumine 4 × 20‐mg Capsules in Healthy Volunteers

Peter Lockwood, Vu Le, Melissa O’Gorman et al. · Clinical Pharmacology in Drug Development · 2020 · 52 citations · Full text

Tafamidis Meglumine 4, Therapeutic Drug Monitoring, Tafamidis 61‐Mg +8